US Stock MarketDetailed Quotes
DTIL Precision BioSciences
- 7.2900
- +0.1800+2.53%
Close Nov 29 13:00 ET
- 7.2900
- 0.00000.00%
Post 17:01 ET
55.92MMarket Cap-26035P/E (TTM)
7.3800High7.1100Low22.29KVolume7.1100Open7.1100Pre Close163.20KTurnover0.36%Turnover RatioLossP/E (Static)7.67MShares19.429952wk High0.86P/B45.51MFloat Cap6.410052wk Low--Dividend TTM6.24MShs Float710.1060Historical High--Div YieldTTM3.80%Amplitude6.4100Historical Low7.3210Avg Price1Lot Size
Precision BioSciences Stock Forum
Sign in to post a comment
$Precision BioSciences (DTIL.US)$
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
Precision BioSciences (Nasdaq: DTIL) announced a virtual Hepatitis B Investor Event scheduled for November 15, 2024. The event will feature Key Opinion Leaders and members of Precision's Hepatitis Scientific Advisory Board discussing the current hepatitis B treatment landscape, which only achieves 1-3% func...
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
Precision BioSciences (Nasdaq: DTIL) announced a virtual Hepatitis B Investor Event scheduled for November 15, 2024. The event will feature Key Opinion Leaders and members of Precision's Hepatitis Scientific Advisory Board discussing the current hepatitis B treatment landscape, which only achieves 1-3% func...
5
$Precision BioSciences (DTIL.US)$
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
Precision BioSciences (Nasdaq: DTIL) presented preclinical data at the ESGCT 31st Annual Congress showcasing their ARCUS platform'scapability for high-efficiency gene editing through homology-directed repair (HDR). The research demonstrated gene insertion rates exceeding 85% ...
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
Precision BioSciences (Nasdaq: DTIL) presented preclinical data at the ESGCT 31st Annual Congress showcasing their ARCUS platform'scapability for high-efficiency gene editing through homology-directed repair (HDR). The research demonstrated gene insertion rates exceeding 85% ...
3
$Precision BioSciences (DTIL.US)$
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
Precision BioSciences (NASDAQ: DTIL) has received its first Clinical Trial Application (CTA) approval in Moldova for PBGENE-HBV, marking the first in vivo gene editing program for chronic hepatitis B virus to enter global clinical trials. The program aims to cure chronic hepatitis B by eliminating ccc...
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
Precision BioSciences (NASDAQ: DTIL) has received its first Clinical Trial Application (CTA) approval in Moldova for PBGENE-HBV, marking the first in vivo gene editing program for chronic hepatitis B virus to enter global clinical trials. The program aims to cure chronic hepatitis B by eliminating ccc...
1
$Precision BioSciences (DTIL.US)$. Reuters· 4 mins ago
Precision BioSciences Inc: Payment Includes $9.75 Mln Cash and $3.25 Mln in Imugene Limited Ordinary Shares Precision BioSciences Receives $13 Million in Proceeds From Imugene Convertible Note Maturity as Part of the August 2023 Azer-Cel Deal
Precision BioSciences Inc: Payment Includes $9.75 Mln Cash and $3.25 Mln in Imugene Limited Ordinary Shares Precision BioSciences Receives $13 Million in Proceeds From Imugene Convertible Note Maturity as Part of the August 2023 Azer-Cel Deal
$Precision BioSciences (DTIL.US)$ $TG Therapeutics (TGTX.US)$ Reuters· just
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
3
$Precision BioSciences (DTIL.US)$ Benzinga· just
Precision BioSciences Announces Common Stock Purchase By Members Of Management, Including CEO, For $300,000 In Private Placement
Precision BioSciences Announces Common Stock Purchase By Members Of Management, Including CEO, For $300,000 In Private Placement
2
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Green Dragon 2024 : Jaguar what’s your opinion on this one? Short, long, future?
Jaguar8 OP Green Dragon 2024 : I have to review the pipeline
Green Dragon 2024 Jaguar8 OP : Would you
… just saw they have er on Monday pm
Jaguar8 OP Green Dragon 2024 : Later I have physical therapy session
Green Dragon 2024 Jaguar8 OP : Not a problem… get some kinetic tape stuff works magic on pain